Side effects of anastrozole in the experimental pre-menopausal mammary carcinogenesis

Neoplasma

Volumn 56, Issue 2, 2009, Pages 124-129

  Sadlonova, V ^a   Kubatka, P ^a   Kajo, K ^a   Ostatnikova, D ^b   Nosalova, G ^a   Adamicova, K ^a   Sadlonova, J ^a  

^a University Teaching Hospital in Martin   (Slovakia)

^b Physics and Informatics   (Slovakia)

Author keywords

Anastrozole; Aromatase inhibitors; Chemoprevention; Female rats; Pre menopausal mammary carcinogenesis; Side effects

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITROSOUREA; PRASTERONE; SEX HORMONE; TESTOSTERONE; TRIACYLGLYCEROL; METHYLNITROSOUREA; NITRILE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BREAST CANCER; BREAST DEVELOPMENT; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENDOMETRIUM ATROPHY; EXPERIMENTAL MODEL; EXPERIMENTAL RAT; EXPERIMENTAL STUDY; FEMALE; FOOD INTAKE; HISTOPATHOLOGY; HORMONE BLOOD LEVEL; LIPID BLOOD LEVEL; LIPID METABOLISM; MYOMETRIUM; NONHUMAN; PREMENOPAUSE; RAT; SPRAGUE DAWLEY RAT; TRIACYLGLYCEROL BLOOD LEVEL; UTERUS WEIGHT; VAGINA EPITHELIUM; WEIGHT GAIN; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EXPERIMENTAL NEOPLASM; PATHOLOGY; UTERUS; VAGINA;

ANIMALS; AROMATASE INHIBITORS; BODY WEIGHT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; NITRILES; RATS; RATS, SPRAGUE-DAWLEY; TRIAZOLES; UTERUS; VAGINA;

EID: 65649141263     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2009_02_124     Document Type: Article

References (29)

1. HONG Y, CHEN S. Aromatase inhibitors: structural features and biochemical characterization. Ann N Y Acad Sci 2006; 1089: 237-251. doi:10.1196/annals. 1386.022 PMid:17261771 (Pubitemid 47092077)
2. MOURIDSEN H, GERSHANOVICH M, SUN Y. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and updates of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21: 2101-2119. doi:10.1200/JCO.2003.04.194 PMid:12775735
3. Paridaens R, Therasse P, Dirix L et al. First-line hormonal treatment (HT) for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients - A randomized phase III trial of the EORTC Breast Group. Proc Am Soc Clin Oncol 2004; 22: 14.
4. Baum M, Buzdar A, Cuzick J. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analysis. Cancer 2003; 98: 1802-1810.
5. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802. doi:10.1056/NEJMoa032312 PMid:14551341 (Pubitemid 37362955)
6. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092. doi:10.1056/ NEJMoa040331 PMid:15014181 (Pubitemid 38298988)
7. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after two years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455-462. doi:10.1016/S0140-6736(05)67059-6 (Pubitemid 41111693)
8. Thürlimann BJ, Keshaviah A, Mouridsen H et al. BIG 1-98: randomized double-blind phase III study to evaluate letrozole versus tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Proc Am Soc Clin Oncol 2005; 23: 16.
9. Smith IE, Dowsett M, Ebbs SR et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double - blind randomized trial. J Clin Oncol 2005; 23: 5108-5116. doi:10.1200/JCO.2005.04.005 PMid:15998903 (Pubitemid 46224019)
10. Cataliotti L, Buzdar A, Noguchi S et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer 2006; 106: 2095-2103. doi:10.1002/ cncr.21872 PMid:16598749
11. Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001; 19: 2767. (Pubitemid 32119104)
12. FREEDMAN OC, VERMA S, CLEMONS MJ. Pre-menopausal breast cancer and aromatase inhibitors: treating a new generation of women. Breast Cancer Res Treat 2006; 99: 241-247. doi:10.1007/s10549-006-9208-x PMid:16752075 (Pubitemid 44337915)
13. RUSSO J, RUSSO IH, ROGERS AE et al. Pathology of tumours in laboratory animals. Tumours of the rat. Tumours of the mammary gland. IARC Sci Publ 1990; 99: 47-78.
14. SADLONOVA V, KUBATKA P, SVECOVA I et al. Tumour suppressive effect of letrozole in mammary carcinogenesis of female rats. Acta Med Martiniana 2007; 7: 9-12.
15. SADLONOVA V, KUBATKA P, KAJO K et al. The model of premenopausal breast cancer: effects of letrozole. Biomed Pap 2007; 151: 75-77.
16. KUBATKA P, SADLONOVA V, KAJO K et al. Preventive effects of letrozole in the model of premenopausal mammary carcinogenesis. Neoplasma 2008; 55: 496-500.
17. VARMA M, CHAI JK, MEGUID MM et al. Effect of estradiol and progesterone on daily rhythm in food intake and feeding patterns in Fischer rats. Physiol Behav 1999; 68: 99-107. doi:10.1016/S0031-9384(99)00152-3
18. PELLEYMOUNTER MA, BAKER MB, McCALEB M. Does estradiol mediate leptin's effects on adiposity and body weight? Am J Physiol 1999; 276: E955-E963.
19. FERRERO S, ABBAMONTE LH, ANSERINI P et al. Future perspectives in the medical treatment of endometriosis. Obstet Gynecol Surv 2005; 60: 817-826.20.
20. MERESMAN GF, BILOTAS M, ABELLO V et al. Effects of aromatase inhibitors on proliferation and apoptosis in eutopic endometrial cell cultures from patients with endometriosis. Fertil Steril 2005; 84: 459-463. doi:10.1016/j. fertnstert.2005.01.137 PMid:16084890
21. STILWILL SE, COOPER BC. Resolution of endometrial hyperplasia with adjuvant anastrozole treatment in postmenopausal breast cancer: a case report. J Reprod Med 2007; 52: 979-980.
22. BELLONE S, SHAH HR, McKENNEY JK et al. Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole. Am J Obstet Gynecol 2008 Jun 10. [Epub ahead of print]
23. VARELAS FK, PAPANICOLAOU AN, VAVATSI-CHRISTAKI N et al. The effect of anastrozole on symptomatic uterine leiomyomata. Obstet Gynecol 2007; 110: 643-649.
24. HARDMAN MP, ROMAN JJ, BURNETT AF et al. Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor. Obstet Gynecol 2007; 110: 518-520.
25. BHATNAGAR AS, BATZL C, HAUSLER A et al. The role of estrogen in the feedback-regulation of follicle-stimulatinghormone secretion in the female rat. J Steroid Biochem Mol Biol 1993; 47: 161-166. doi:10.1016/0960-0760(93)90070-D PMid:8274431
26. SINHA S, KASETA J, SANTNER SJ et al. Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat. Breast Cancer Res Treat 1998; 48: 45-51. doi:10.1023/A:1005937900788 PMid:9541188
27. Bernstein LM, Larionov AA, Kyshtoobaeva AS et al. Aromatase in breast cancer tissue localization and relationship with reproductive status of patients. J Cancer Res Clin Oncol 1996; 122: 495-498. doi:10.1007/BF01187162 PMid:8698750
28. Bulun WR, Sharda G, Rink J et al. Distribution of aromatase P450 transcripts and adipose fibroblasts in the human breast. J Clin Endocrinol Metabol 1996; 81: 1273-1277. doi:10.1210/jc.81.3.1273 (Pubitemid 26084463)
29. Yue W, Wang JP, Hamilton CJ et al. In situ aromatization enhances breast tumour estradiol levels and cellular proliferation. Cancer Res 1998; 58: 927-932.